The 340B Drug Discount Program started in 1992 with the laudable intention of helping federally funded hospitals that serve a large number of uninsured patients cover the costs of drugs and provide discounts to patients. However, due to the lack of a clear definition of an eligible patient and poor oversight, the program has drifted […]
Eliminating waste, fraud, and abuse continues to be a priority across the legislative and executive branches of the federal government. Lawmakers who are fighting against wasteful spending should agree to eliminate an outdated and unnecessary rule that would result in the modernization of how critical medical information is transmitted. It would both bring common sense […]
As Americans prepare to celebrate the 250th anniversary of the nation’s founding, the festivities should include recognition of the United States as the global leader in biopharmaceutical development and innovation. However, America’s place atop the globe is being challenged by government intervention, specifically provisions in the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) […]
The U.S. boasts the most innovative biopharmaceutical industry in the world. These companies deliver vital cures to patients and the majority of sales the industry make are made by domestic companies. But that global leadership in a critical industry was challenged in May 2025, when the Department of Commerce announced it was initiating an investigation […]
Americans are continually worried about the cost of healthcare. There are a plethora of good and bad ideas to make healthcare more affordable, including Most Favored Nation (MFN) price controls, which would import prices for pharmaceuticals from other countries, many of which rely on socialized medicine and government-run healthcare. But price controls in any industry, […]
Congress created the 340B program in 1992 to fix a problem it had created two years earlier when it implemented price controls, or rebates, in the Medicaid drug benefit program. As a condition to participate in Medicaid, pharmaceutical companies must also partake in the 340B program, giving significant discounts of between 20-50 percent, to certain federally-funded […]
February 3, 2026 Marty Makary Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Dear Commissioner Makary, Thank you for your ongoing work to ensure the safety and efficacy of pharmaceuticals for all Americans. We are grateful for your diligent enforcement of President Trump’s vision to […]
The United States is the global leader in developing innovative and life-saving cures and treatments thanks to the investments made by pharmaceutical companies in the United States, including the vaccines that helped end the coronavirus pandemic. Vaccines are crucial to the physical and economic health of not just Americans but also people across the rest […]
The 340B Drug Discount Program was given the laudable goal of helping federally funded clinics and public hospitals that serve a large uninsured population cover the cost of drugs and provide discounts to patients. However, like many other well-intended federal programs 340B has gone off the rails due to the lack of clear intent and […]
President Trump has made lowering drug prices and reducing healthcare costs for Americans a top priority of his second term, along with encouraging more biopharmaceutical investment and innovation in the U.S. Citizens Against Government Waste suggests that he can achieve both objectives without imposing price controls, which includes Most Favored Nation (MFN) polices, reforming the […]
